Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Biological monitoring screening of patients provided antineoplastic drugs including adriamycin, cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine.

Authors
Newman-MA; Hee-SQ; Schoeny-R; Lowry-L
Source
Cancer Res 1990 Jun; 50(11):3351-3366
NIOSHTIC No.
00209914
Abstract
Screening biomarkers of exposure to antineoplastic drugs were established. The anticancer drugs that were administered to 11 patients undergoing cancer chemotherapy included cyclophosphamide, adriamycin, methotrexate, vincristine, 5-fluorouracil, megestrol- acetate, and/or procarbazine. The urinary parameters that were assessed included thioethers, D-glucaric-acid, elements, and forward and reverse mutagenesis using bacterial bioassays. Data were analyzed in terms of concentrations observed and corrected for personal baseline. Personal baseline correction for the parameters with significant nonexposure baseline levels proved essential. Glucaric-acid was influenced by methotrexate and vincristine. Thioether content was affected by cyclophosphamide. The forward mutagenesis assay was directly correlated to cyclophosphamide dose, but the reverse assay was not. Elements affected by the anticancer drugs relative to controls included potassium, sulfur, phosphorus, calcium, magnesium, sodium, and/or carbon. The authors conclude that the forward mutagenesis assay and D-glucaric-acid concentrations were the best screening biomarkers for monitoring exposure to antineoplastic drugs.
Keywords
NIOSH-Author; Biological-monitoring; Screening-methods; Antineoplastic-agents; Therapeutic-agents; Exposure-levels; Urinalysis
CODEN
CNREA8
Publication Date
19900601
Document Type
Journal Article
Fiscal Year
1990
NTIS Accession No.
NTIS Price
Issue of Publication
11
ISSN
0008-5472
Source Name
Cancer Research
TOP